FSSAI noticed Dr Reddy's and Nestlé's Celevida GLP+ over therapy-linked claims

On October 8, 2026, India's food regulator FSSAI issued notices to Dr Reddy's Laboratories, Nestlé Health Science and e-commerce platforms over allegedly non-compliant advertising and health claims for Celevida GLP+, a high-protein nutritional supplement marketed to people undergoing GLP-1/GIP therapy. The product was launched in May 2026 by the venture between Dr Reddy's and Nestlé Health Science, positioned to support nutrition and muscle-mass maintenance among people taking GLP-1 drugs for weight management and diabetes.

FSSAI said the claim of high protein support for lean muscle preservation during GLP-1/GIP therapies could imply suitability for a specific physiological condition, and flagged the brand name Celevida GLP+ itself for creating a potentially misleading association with the therapies. Also questioned: Help Maintain Lean Muscle, support muscle strength, preserves lean mass, and imported from Europe for purity. Notices also went to Flipkart India, Amazon India, Netmeds Healthcare and Tirupati Wellness over the claims shown beside the product online.

The notices seek the companies' explanations before any further regulatory action, and FSSAI noted their issuance does not by itself establish a final violation. The action lands in a market where benefit-led positioning is the norm: the regulator said the matter concerns how nutritional supplements are presented to consumers, and it follows other FSSAI actions over misleading claims, including against Dabur India.

Regulatory notices to both makers and to Flipkart, Amazon India, Netmeds and Tirupati Wellness, with further action pending responses.

The brand name GLP+ and the therapy-specific claims tied a food supplement to prescription drug therapies, an association FSSAI read as potentially misleading.

Claims like 'preserves lean mass' during weight-loss therapy implied the product mitigates a clinical effect of the drugs, going beyond describing nutritional composition.

The 'imported from Europe for purity' claim invoked an unverifiable quality virtue, which the regulator identified as potentially misleading.

The advertising ran on major e-commerce platforms, putting the sellers themselves under scrutiny for the claims shown beside the product.

Riding a drug category's name is a claim in itself: when a supplement brands itself after a therapy, the regulator reads the label as a promise the product cannot legally make.

The companies and platforms were given the opportunity to respond before FSSAI considers further action; no penalty had been imposed as of the regulator's October 8, 2026 statement. The case sharpened the line FSSAI drew between describing a product's nutrition and associating it with a treatment or physiological outcome, and added the GLP-1 economy — supplements pitched alongside blockbuster weight-loss drugs — to the regulator's enforcement watch.